<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>23(6)</volume><submitter>Hall VG</submitter><funding>the Ajmera Transplant Centre</funding><pubmed_abstract>The optimal management of immunosuppression in transplant patients infected with COVID-19 is unknown. We performed an in vitro study to determine the effect of individual immunosuppressive agents on SARS-CoV-2-specific T-cell cytokine expression. Convalescent peripheral blood mononuclear cells from eleven non-immunosuppressed patients with COVID-19 were preincubated with clinically relevant concentrations of immunosuppressive drugs (tacrolimus, mycophenolate, sirolimus, prednisone) and then stimulated with a SARS-CoV-2 peptide pool. Supernatants were analyzed by 14-plex high sensitivity T-cell cytokine array. With increasing concentrations of tacrolimus, there was a trend to reduction in the release of IL-2 (p = .0137), and IFN-γ (p = .0147) in response to peptide stimulation. There was al</pubmed_abstract><journal>Transplant infectious disease : an official journal of the Transplantation Society</journal><pagination>e13743</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC8646571</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Impact of immunosuppression on the immune response to SARS-CoV-2 infection: A mechanistic study.</pubmed_title><pmcid>PMC8646571</pmcid><pubmed_authors>Kumar D</pubmed_authors><pubmed_authors>Hall VG</pubmed_authors><pubmed_authors>Humar A</pubmed_authors><pubmed_authors>Ferreira V</pubmed_authors></additional><is_claimable>false</is_claimable><name>Impact of immunosuppression on the immune response to SARS-CoV-2 infection: A mechanistic study.</name><description>The optimal management of immunosuppression in transplant patients infected with COVID-19 is unknown. We performed an in vitro study to determine the effect of individual immunosuppressive agents on SARS-CoV-2-specific T-cell cytokine expression. Convalescent peripheral blood mononuclear cells from eleven non-immunosuppressed patients with COVID-19 were preincubated with clinically relevant concentrations of immunosuppressive drugs (tacrolimus, mycophenolate, sirolimus, prednisone) and then stimulated with a SARS-CoV-2 peptide pool. Supernatants were analyzed by 14-plex high sensitivity T-cell cytokine array. With increasing concentrations of tacrolimus, there was a trend to reduction in the release of IL-2 (p = .0137), and IFN-γ (p = .0147) in response to peptide stimulation. There was al</description><dates><release>2021-01-01T00:00:00Z</release><publication>2021 Dec</publication><modification>2025-04-04T09:42:05.658Z</modification><creation>2022-02-11T13:49:07.32Z</creation></dates><accession>S-EPMC8646571</accession><cross_references><pubmed>34668283</pubmed><doi>10.1111/tid.13743</doi></cross_references></HashMap>